GlassScriptPhysician profile
Brandon M Saunders
NPI 1598158560
$7,873.26
in general payments reported to CMS, 2019-2025
55 companies · $1,797 in 2025
The $1,797 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108 · 2022: $2,167 · 2023: $2,004 · 2024: $1,797 · 2025: $1,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,598.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,427.30 | 2021-2025 | |
| Novo Nordisk INC | $1,199.40 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $727.53 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $486.26 | 2021-2024 | Repatha, Otezla |
| Lilly USA, LLC | $410.79 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $356.00 | 2022-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.22 | 2022-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $219.81 | 2022-2024 | Rexulti |
| Antares Pharma, INC. | $192.58 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $177.90 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $168.28 | 2022-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $155.76 | 2022-2023 | |
| Astellas Pharma US INC | $152.23 | 2023-2025 | Veozah, Myrbetriq |
| Xeris Pharmaceuticals, INC. | $151.43 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Medtronic, INC. | $114.26 | 2022-2025 | Minimed 780g |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Saunders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.